We produced a monoclonal antibody (C2-22) 
However,becausethe ratio of Ape Al to Ape All is higher in HDL2 than in HDL3, increased ratios of plasma Ape AllAH usually reflect higher concentrationsof HDL2 than of HDL3 (9) . In addition to its use in epidemiologicaland diagnostic situations,the Ape AllAH ratio may be useful in assessing therapy. Studying patients treated with bile-acid-binding resins, Witzum et al. (10) found no changes in the HDL cholesterol,but noted an increase in the Ape Al/All ratio, suggestiveof a redistribution of cholesterolfrom HDL3 to
}LDL2.
Among the immunoassay techniques used for measuring Ape All are radioimmunoassay (11-13), electroimmunoassay (14), radial immunodiffusion (15) , and, more recently,
enzyme-linked immunoabsorbant assays (ELISA) (16-18).
The differences in concentrations in serum reported for Ape All probably reflect differences in techniques, standardization, antibody specificity, and patient population studied. In a recently reported competitive EUSA system for Ape All, Dufaux et al. (18) used an enzyme-labeled purified Ape All tracer and solid-phase-bound anti-Ape All polyvalent rabbit antiserum.
We describe here an improved competitive inhibition ELISA system for quantifying Ape All in human plasma. We use a monoclonal antibody to Ape All, and purified Ape All is not required for labeling as "tracer" or for standards.
Materials and Methods

Preparatory Procedures
Isolation and purification of Apo All: IIDL was isolated from the plasma of normal volunteers by ultracentrifugal flotation between densities of 1 Corp., La Jolla, CA). The resulting antiserum was collected and stored at -20 #{176}C. We checked the specificity of the antiserum by reacting it with known purified apolipoproteuns, selected lipoprotein fractions, and albumin.
Radioimmunoassay procedure for Apo All measurement:
We iodinated purified Ape All by the Chiorainine T method (20) , using 2 pg of Ape All, 0.5 mCi of 'I (New England Nuclear, Boston, MA), and 87.5 pg of Chlorainine T. After 30 a, we stopped the reaction by adding 250 pg of sodium metabisulfite. Radiolabeledprotein was separated from unbound iodine on a 1 x 23 cm column of G-50 (Pharmacia, mc, Piscataway, NJ).
Purified Ape All standards or plasma samples, diluted rabbit or mouse antiserum to Ape All (or monoclonal antibody to All), and 'I-labeled Ape AU were combined and incubated overnight. The next day, we added antiserum to rabbit or mouse IgG (Miles Laboratory, Elkhart, IN) to all samples, to separate bound and free tracer. We counted the radioactivity of the bound fraction in a gamma counter (Packard "Multi-Prias 1"; United Technologies, Downers Grove, IL).
Development of the monoclonal antibody to Apo All: The procedures used were adapted from those of Kohier and Milstein (21) . Spleen cells from C57/Balb-C Fl mice that had been immunized with purified Ape All were fused with SP/2 myeloma cells, and the resulting hybridomas were screened for antibody to Ape All. This procedure was similar to the RIA procedure described above except that we We totally displaced the antibody from the solid-phasebound Ape All by adding 1 pg of Ape All. To assess specificity of the monoclonal antibody, we determined its crossreactivity with other purified apelipeproteins (Ape Al, CI, CII, Cm, and E), selected lipoprotein fractions (VLDL, LDL, HDL, HDL2, and HDL3), whole plasma, and albumin.
We also assessedthe reactivity (binding) of the monoclonal antibody with Ape All isoforms isolated from Apo-HDL by isoelectric focusing (19). C2-22 bound to all four Ape AU isoforms. To determine if glutaraldehyde increased Ape All binding, we pre-treated half the wells of two plates with glutaraldehyde before coating with antigen; the wells were ifiled (to the top) with a 1 g/L solution of glutaraldehyde in distilled water, incubated for 5 miii at 23 #{176}C, washed three times with distilledwater, and suctioned dry. Treatment with glutaraldehyde increased the absorbance of the assay by 35% and decreased the between-wells CV by approximately 2%. All plates were subsequently pretreated with glutaraldehyde.
Preparation of solid-phase-bound
Competitive ELISA for Apo All quantitation:
Plasma samples were diluted 500-fold in PBS/bovine serum albumin.
Purified Ape AU or a serum calibrator (ApoCal All) was used for the standard curve, concentrations for which ranged from 0.1 to 6 g/L. Diluted sample (standard or unknown) were assayed in triplicate with 50 pL per well.
This was immediately
followed by the addition of 50 pL of the monoclonal antibody (diluted i:i0 in PBS/albumin). Plates were covered and incubated for 2 h at 23 #{176}C, washed three times with PBS/albumin, and 100 pL of the alkalinephosphatase-conjugated rabbit anti-mouse immunoglobulin, diluted 400-fold in PBS/albumin, was added to each well. The plates were incubated for 1 h at 23#{176}C and washed and dried as before. Then substrate was added and color developed as described previously, and the plates were read in an ELISA reader (Artek Systems Corp., Farmingdale, NY) at 405 nm. A standard curve was constructed by plotting absorbance (y-axis) vs log Ape AU (x-axis). 
Lipid and Apo Al and B measurements:
Total HDL cholesterol was measured by a microenzymatic assay (22) , standardized to the Lipid Research Clinics procedure by using a serum calibrator supplied by the Centers for Disease Control (23) . HDL was isolated by use of the modified LRC heparun-MnCl2 procedure (24) , adapted to use with 200 pL of plasma (22) . Triglycerides were measured by a microenzymatic procedure as previously described (22) . Ape Al and B were quantified by electroimmunoassay (19).
Results
Specificity of monoclonal antibody C2-22 to Apo All: Displacement of the monoclonal antibody was assessedby use of increasing concentrations of Ape All. Displacement was minimal (10%) with less than 0.10 mg of pure Ape AU per liter (5 ng per well) and maximal (100%) with 1.5 mgfL (75 ng per well). There was no detectable displacement (0% cross reactivity) with Ape CI, CII, Cm, E, or albumin. Ape Al produced 50% displacement at a concentration approximately 400 times that of Ape AU (0.25% cross reactivity). LDL and VLDL produced displacement of Ape AU only at very high concentrations (cross reactivities of <0.2% and <0.3%, respectively). Whole plasma and HDL and its subfractions HDL2 and HDL3 produced parallel displacement to Ape AU, based on their total-protein content (25) .
Assessment of the ELISA procedure: Figure 1 illustrates a typical standard curve obtained with the plasma calibrator (ApeCal All). We determined the Ape U content of ApoCal All by repeated measurements in the ELISA system, using a primary standard of purified Ape AU isolated by isoelectric focusing for which the mass was quantified by amino acid analysis. Although a seven-point curve was run, shown in Figure 1 , we used only values falling within the rectilinear center five points for the "standard" curve. We re-analyzed samples with values falling outside of this range, using different dilutions. The effective working range for plasma samples for the assay was therefore 140 to 1140 mg/L (equal to 0.3 to 2.3 mgfL after patients' samples are diluted 500-fold).
For all samples, delipidation resulted in a decrease of 32-70% in Ape AU concentration measurable by either the ELISA or the polyvalent RIA procedure (Table 1) . There was also a consistent loss of protein (as measured by the Lowry method) in the delipidation procedure, although this loss By procedure of Lowry et al. (25) . bA, whole plasma; B, delipidated plasma.
was proportionately much less (6-10%).
The within-run CVs at 327 and 587 mg of Ape AU per liter were respectively 8.4 and 6.8%. Between-run precision showed only slightly higher CVs for the two pools ( Table 2) .
Correlation of monoclonal ELISA with RIA: In Figure 1 we compare the displacement (standard) curves for the ELISA procedure with those obtained by two RIA procedures. The pelyclonal RIA is more sensitive and the curve has a different slope, indicating either recognition of different or multiple antigenic sites or a different affinity for Ape All. RIA with use of the same monoclonal antibody as in the SUM procedure gave a parallel curve with SUM (Figure 1) .
We also compared the monclonal ELISA and pelyvalent RIA, using 41 patients' samples. The correlation coefficient Plasma Apo All concentrations in patients' samples: Plasma Ape All values in 38 laboratory staff, ages 22-49 years, and 18 subjects with type II phenotype are shown in Table 3 , together with their lipid and Ape Al and B concentrations. For Ape All, no statistically significant sex-related differences were seen; HDL cholesterol and Ape Al tended to be higher and LDL cholesterol and Ape B slightly lower in women. The type II subjects had markedly increased LDL cholesterol and Ape B, and decreased values for HOL cholesterol, Ape Al, and Ape AU. Table 4 shows results for the 176 fasting subjects who were undergoing routine plasma lipid/lipeprotein evaluations, several of whom were known to have lipeprotein abnormalities.
To assess relationships
between Ape AU and the other lipoprotein fractions, we did a regression analysis. There 
Discussion
This EUSA technique has several advantages over previously described procedures (11-15) . The amount of antisera used in radial immunodiffusion and electroimmunoassay is and electroimmunoassay, no difficult to detect and imprecise endpoint is involved. Although nephelometry requires less analytical time than the present procedure, and also is potentially automatable, it is subject to significant inherent light-scattering interference, especially with lipemic samples (26) . RIA is extremely sensitive, subject to minimal interference, and allows simultaneous analysis of many samples, but it requires substantial time and effort to maintain, owing to the short-lived labeled antigen tracer. In addition, the low-level radiation is potentially hazardous and logistically awkward to handle.
Our SUM system differs from that described by Dufaux et al. (18) : it requires no enzyme labeling of purified Ape All antigen, which is time consuming and may result in aggregation or alteration of the immunogenic properties of the apelipeprotein; and our use of a high-affinity monoclonal antibody ensures long-term uniformity for the procedure. Apparently, the monoclonal antibody (C2-22) recognizes a "surface" antigenic site (pan-antibody) and no additional epitopes are exposed by delipidation. This ability to quantify total plasma Ape AU without sample treatment is shared by assays in which pelyvalent antisera are used (11-15, 18) .
Disadvantages of our assay are the additional washing steps and the second-antibody addition. The reported intraassay precision is similar for both procedures, but our between-assay precision represents an almost 50% improvement over that reported by Daufaux et al. (18) . This may in part be related to the inherent "stability" of our system (no enzyme-labeled antigen, monoclonal antibody) and the fact that our assays are run in triplicate, vs duplicate for the procedure of Dufaux et al. Small variations in antibody coating appear to affectthe procedure of Dufaux et al. notably, but have no such effect on our assay.
Our studies on whole and delipidatedsera confirm those of others (11, 18, 27) in that no increase in Ape AU ws measurable after delipidation. The decreased values for Ape All as measured by both ELISA and RIA probably are a result of apoprotein loss during the delipidation procedure, because total protein also was decreased-and immunechemical alteration resulting from delipidation may also partly explain these results. Possibly, alternative delipidation procedures such as those involving ethanol:ether (28) The values for Ape AU in plasma of patients with lipid abnormalities (Table 4 ) and of normal laboratory volunteers (Table 3) are somewhat higher than those previously reported in the literature (11-16). However, the Ape Al and HDL cholesterol values for the volunteers are also well above those usually reported, while their Ape Al/All ratio of 2.6 (for men) and 2.92 (for women) is about average. These higher values may be biased by the small size of the group of subjects or, alternatively, by the assay calibration procedure as a consequenceof the assigned value of the serum calibrator, ApoCal All. The specific (type II) and general patient population had lower values for Ape AU and HDL cholester-ol, as would be expected. The lack of sex-related difference is consistent with the lack of a sex-related difference in HDL cholesterol. The general group of patients did, however, include subjects with known lipid abnormalities, some of whom were undergoing therapy with diet or drugs. Thus, their lack of conformity to previously published lipid and apolipoprotein population distributions might be expected. There was, as expected, a strong statistical correlation between HDL cholesterol and Ape All (r = O.5Ol;p <0.001) and no relationship between Ape All and either LDL cholesterol (r = -0.098; p = 0.223) or triglycerides (r = -O.ll8;p = 0.118). The within-and between-run precision studies demonstrated CVs of <10% for both the lower concentration of Ape All (327 mgfL) and the higher (587 mg/L). There are numerous manual steps involved in this procedure, and automation would most likely increase the precision.
The present monoclonal SLIM is not a sensitive as our own pelyvalent RIA or the RIAs reperted by others (11, 12,  30 ), but more than suffices for quantification of Ape All in plasma or lipeprotein subfractions (e.g., HDL2 or HDL.3).
In conclusion: the system described here is sensitive, specific, and precise. It requires no pretreatment of plasma, a serum-based calibrator can be used, and no labeling of Ape All or anti-All is necessary. Maintenance is minimal, the assay is stable for many months, and it is rapid and fairly simple to perform. Finally, because it is potentially automat.able, large numbers of samples potentially may be quickly and inexpensively assayed.
